B. Riley Forecasts Lower Earnings for Denali Therapeutics

Denali Therapeutics Inc. (NASDAQ:DNLI) – Analysts at B. Riley reduced their Q2 2025 earnings per share estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.80) per share for the quarter, down from their prior estimate of ($0.79). B. Riley currently has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics’ FY2025 earnings at ($2.72) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($1.38) EPS and FY2028 earnings at ($2.05) EPS.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08.

Other equities analysts have also recently issued reports about the company. Morgan Stanley started coverage on Denali Therapeutics in a report on Friday. They issued an “overweight” rating and a $33.00 target price on the stock. HC Wainwright increased their target price on Denali Therapeutics from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Monday, December 16th. Oppenheimer cut their target price on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Finally, The Goldman Sachs Group cut their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $37.27.

Denali Therapeutics Stock Up 2.6 %

Shares of DNLI opened at $16.69 on Friday. Denali Therapeutics has a 12-month low of $14.01 and a 12-month high of $33.33. The business’s fifty day moving average is $20.88 and its 200 day moving average is $24.35. The stock has a market cap of $2.40 billion, a P/E ratio of -6.05 and a beta of 1.43.

Institutional Investors Weigh In On Denali Therapeutics

Several large investors have recently added to or reduced their stakes in DNLI. Sterling Capital Management LLC increased its holdings in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Denali Therapeutics in the 4th quarter worth about $62,000. Point72 Hong Kong Ltd purchased a new stake in Denali Therapeutics in the 4th quarter worth about $65,000. Quest Partners LLC purchased a new stake in Denali Therapeutics in the 3rd quarter worth about $73,000. Finally, PNC Financial Services Group Inc. increased its holdings in Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after acquiring an additional 885 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Insider Activity

In related news, insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the sale, the insider now owns 178,580 shares of the company’s stock, valued at approximately $3,610,887.60. This trade represents a 6.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock valued at $973,442 in the last ninety days. 7.90% of the stock is currently owned by insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.